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 14 
Abstract 15 
Disease maps are effective tools for explaining and predicting patterns of disease outcomes 16 
across geographical space, identifying areas of potentially elevated risk, and formulating and 17 
validating aetiological hypotheses for a disease. Bayesian models have become a standard 18 
approach to disease mapping in recent decades. This article aims to provide a basic 19 
understanding of the key concepts involved in Bayesian disease mapping methods for areal 20 
data. It is anticipated that this will help in interpretation of published maps, and provide a 21 
useful starting point for anyone interested in running disease mapping methods for areal data. 22 
The article provides detailed motivation and descriptions on disease mapping methods by 23 
explaining the concepts, defining the technical terms, and illustrating the utility of disease 24 
 
 
 
 
 
2 
mapping for epidemiological research by demonstrating various ways of visualising model 25 
outputs using a case study. The target audience includes spatial scientists in health and other 26 
fields, policy or decision makers, health geographers, spatial analysts, public health 27 
professionals, and epidemiologists. 28 
 29 
Introduction 30 
Disease mapping is a flourishing field due to the growing amount of routinely collected 31 
health information worldwide (Rytkönen, 2004). Advances in geographic information 32 
systems have greatly aided the analytical manipulation and visual representation of spatial 33 
data (Burroughs and McDonnell, 1998). Spatial information in health is especially useful for 34 
informing the locations of disease occurrences and the onus is on making the best possible 35 
use of this information.  36 
Some excellent introductory guides for disease mapping are available in the literature. 37 
Nonetheless, many of these are either not intended for non-statistical audiences, or lack 38 
specific details. For instance, Elliot et al. (2000) present a comprehensive review of the 39 
recent developments in spatial epidemiology but the statistical methods require a level of 40 
background knowledge which may not be suitable for beginners. Marshall (1991) covers a 41 
broad range of methods for the analysis of the geographical distribution of disease, rather 42 
than upskill the reader in using particular methods. Lawson and Williams (2001) provide a 43 
broad overview of the issues concerning disease mapping but is short on specifics (English, 44 
2001). Banerjee et al. (2014) presents a fully model-based approach to all types of spatial 45 
data, including point level, areal, and point pattern data. Cramb et al. (2011b) offer insight 46 
into the decisions made in generating a health atlas, but is not intended as an entry-level 47 
article for a non-statistical audience. This article fills the niche by providing motivation, 48 
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definition and description at a general level, and illustrating these ideas via a substantive case 49 
study.  50 
 Although disease mapping has been undertaken in various forms for over 100 years, 51 
the opportunity now exists to use model-based maps that acknowledge uncertainty in inputs 52 
and outputs (López-Abente et al., 2014; Catelan and Biggeri, 2010), take account of the 53 
spatial nature of the data to ‘borrow strength’ from neighbouring areas in order to improve 54 
small area estimates, and can provide probability statements (Goovaerts, 2006b). In this 55 
article, we describe Bayesian disease mapping for areal data (Lawson, 2001, 2009) as an 56 
approach that addresses these issues. We focus on a running example of mapping cancer, 57 
although the methods are applicable to other diseases.  58 
 The primary purpose of this article is to provide a basic understanding of the key 59 
concepts involved in Bayesian statistical models for disease mapping of areal data. We 60 
commence with a discussion of why disease model-based mapping methods are required. 61 
Background on Bayesian methods typically used for disease mapping is then provided, and 62 
then some of the cartographic outputs commonly used are discussed, including methods for 63 
indicating statistical uncertainty in relative risk (see Glossary) of disease.  64 
  65 
Case Study: Cancer in Australia  66 
Cancer is now the world’s and Australia’s biggest killer (IARC, 2014). The number of cases 67 
diagnosed continues to increase worldwide due to population growth and aging, with the 68 
increasing prevalence (see Glossary) of physical inactivity, poor diet and reproductive 69 
changes (such as later parity) also contributing (Torre et al., 2015). In Australia, cancer 70 
accounts for almost one-fifth (19%) of the total disease burden (AIHW, 2014).  71 
Disparities in cancer outcomes across broad socioeconomic status and urban/rural 72 
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categories have been reported internationally (Wilkinson and Cameron, 2004; Woods et al., 73 
2006; Ernst et al., 2010). Within Australia, there are disparities in cancer outcomes with 74 
respect to geographic remoteness and socioeconomic status (AIHW, 2014). Cancers such as 75 
cervical and lung had higher incidence (see Glossary) and mortality as remoteness or area-76 
level disadvantage increased. Furthermore, the five-year relative survival from all cancers 77 
combined decreased with greater remoteness and greater socioeconomic disadvantage.  78 
 Understanding disparities in these broad areas, while useful, is unlikely to accurately 79 
reflect the heterogeneity in outcomes at the local level. Efforts to monitor and reduce cancer 80 
disparities can benefit greatly from quantifying variation across population groups and 81 
pertinent, small geographical areas. An understanding of the geographic patterns of cancer 82 
enables health decision-making by health service planners, clinicians, epidemiologists and 83 
industry groups to be more accurate and effective, for example by targeting policy 84 
development and resource allocation at areas of greater need (Mason et al., 1975; Kulldorff et 85 
al., 2006).  86 
 Cramb et al. (2011a) produced the first Atlas of Cancer in Queensland to describe 87 
geographical variation in cancer incidence and survival across small areas in Queensland, 88 
using routinely-collected health information from the Queensland Cancer Registry. For the 89 
first time, Bayesian model-based cancer incidence and survival maps for Queensland were 90 
systematically presented at a comprehensive level. The Atlas significantly contributed to the 91 
understanding of geographical variation of cancer incidence and survival across Queensland, 92 
and subsequently influenced government policy decisions.  93 
 94 
Methods  95 
Disease maps are a visual representation of disease outcomes. The use of disease maps to aid 96 
 
 
 
 
 
5 
decision making in epidemiological and medical research is well recognized (Koch, 2011). 97 
Disease maps are effective tools for explaining and predicting patterns of disease outcomes 98 
across geographical space, identifying areas of potentially elevated risk, and formulating and 99 
validating aetiological hypotheses for a disease (Shen and Louis, 2000). They are able to 100 
uncover local-level inequalities frequently masked by health estimates from large areas such 101 
as states, regions or cities (Borrell et al., 2010),  enabling the development of disease 102 
reduction and prevention programs targeting high-risk populations, see for instance, Mason et 103 
al. (1975) and Kulldorff et al. (2006) who have used cancer maps to depict the geographic 104 
patterns of cancer outcomes.  105 
 Disease mapping encompasses small area studies that use data aggregated over small 106 
areas and take into account local spatial correlation, see for example, Clayton and Kaldor 107 
(1987); Cressie and Chan (1989); Besag et al. (1991) and Bernadinelli et al. (1997). Data 108 
sparseness is common in small area analyses, especially when working with less common 109 
diseases. A small number of observed and expected disease occurrences leads to unstable risk 110 
estimates (Ancelet et al., 2012).  111 
 The problem of potentially unstable risk estimates for sparse spatial data needs to be 112 
mitigated to obtain reliable estimates. In practice, this is achieved by implementing spatial 113 
smoothing techniques. Spatial smoothing effectively “borrows strength” across small areas, 114 
so that the disease rate estimated for an area with a small population denominator would be 115 
weighted towards the estimated disease rate of neighbouring areas that have larger 116 
denominators. The estimates obtained by smoothing information from neighbouring areas are 117 
more reliable and robust due to the increased precision in the risk estimates in areas with few 118 
observations (Ancelet et al., 2012). In the context of disease mapping for small areas, the 119 
implementation of spatial smoothing is commonly achieved via the incorporation of a 120 
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conditional autoregressive prior distribution for the spatial effects (see Lee (2011) and the 121 
“Bayesian Spatial Statistical Models” section for details). 122 
  A disease mapping model is essentially a regression model that links a disease 123 
outcome to a set of risk factors (see Glossary). An important concept in disease mapping 124 
models (which is common to many other regression (see Glossary) models) is the use of 125 
random effects (see Glossary). In this context, random effects provide a way of estimating 126 
variation in disease risk between areas that is not otherwise captured by known risk factors 127 
(e.g. age, sex, socioeconomic status, etc.).  128 
 129 
Why Bayesian?  130 
Bayesian statistics takes its name from the English clergyman Thomas Bayes (1702-1761), 131 
although the key concepts were also contemporaneously established by Laplace and 132 
embedded in the general view of ‘inverse probability’ at that time (Bernardo and Smith, 133 
2009). It is an approach to data analysis that focuses on relating observed and unknown 134 
quantities using conditional probabilities, which are measures of the probability of an event 135 
given that another event has occurred.  136 
 In a Bayesian model (see Box 1), an unknown parameter (see Glossary) is represented 137 
using a distribution rather than a single point estimate (Johnson, 2004). The model 138 
parameters have distributions and are probabilistic (e.g. parameters representing coefficients 139 
associated with covariates (see Glossary) in a regression model might be given a Normal 140 
distribution (see Box 2)). These distributions are known as prior distributions (see Glossary). 141 
These prior distributions can be considered as representing the uncertainty about the 142 
parameter before the data are seen. The parameters in the prior distributions (e.g. the mean 143 
and variance of the prior on a regression coefficient) can also have distributions which are 144 
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known as hyperprior (see Glossary) distributions. Again, these distributions also represent 145 
uncertainty about our knowledge of these values. The combination of the prior information 146 
and the data results in a posterior distribution (see Glossary). The posterior distribution can 147 
be thought of as a probability distribution on the values of an unknown parameter that 148 
combines prior knowledge about the parameter and the observed data. The Bayesian model 149 
thus consists of parameters related to one another in the form of a hierarchy. The complex 150 
nature of spatial data can be captured using this hierarchical structure (see Glossary) (Shen 151 
and Louis, 2000; Best et al., 2005). 152 
 Random effects are generally included in these models. Typically, a random effect is 153 
specified as being Normally distributed, whereby a few areas are allowed to have a disease 154 
incidence much lower than expected based on these risk factors, a few areas much higher, but 155 
most are close to expected (following a bell curve). For spatial data, we assume that sites 156 
closer to each other are more similar, so we can use information from neighbouring sites to 157 
obtain better estimates of disease risk. Hence, when we fit a spatially-correlated random 158 
effect, the variation at a particular site is Normally distributed relative to the mean of its 159 
neighbours. These random effects thus relate disease risk estimates to neighbouring 160 
estimates, producing a ‘smoothing’ effect across the area of interest.  161 
 There are many reasons why the Bayesian approach is a useful framework for disease 162 
mapping. Firstly, Bayesian smoothing methods produce robust and reliable estimation of 163 
health outcomes of interest in a small area, even when based on small sample sizes (Ancelet 164 
et al., 2012). Within these small areas, the sample sizes are sometimes too small to yield 165 
estimates with adequate precision and reliability. Bayesian smoothing techniques improve the 166 
estimation by using information from neighbouring areas.  167 
 Secondly, the use of prior distributions (usually based on existing knowledge or 168 
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expert opinion) in disease mapping models helps strengthen inferences (see Glossary) about 169 
the true value of the parameter and ensures that all relevant information is included (Gurrin et 170 
al., 2000). These can be ‘uninformative’ (e.g. set to be Normally distributed with a mean of 171 
zero and a very large variance) or ‘informative’ if there is other information about the effect 172 
of this risk factor (given the other risk factors in the model). Thirdly, the Bayesian approach 173 
allows for quantification of the uncertainty related to the health estimates from the posterior 174 
distributions (Ghosh et al., 1999; Wakefield, 2007). Spatial uncertainties added to the 175 
resulting risk maps depict local details of the spatial variation of the risk and provide valuable 176 
information for policy makers to make decisions about thresholds and public health 177 
(ApSimon et al., 2002; Johnson, 2004; Goovaerts, 2006b).  178 
 Lastly, direct probabilistic statements can be made about the underlying and 179 
unobserved parameters of interest using their posterior probability distributions. In disease 180 
mapping, it might be of interest to make probability statements about areas of high risk for a 181 
disease. For instance, computing and mapping probabilities that the risk in an area exceeds 182 
certain thresholds can be done using the posterior probability distributions (Green and 183 
Richardson, 2002). This probability of exceedance can then be used to decide whether an 184 
area should be classified as having excess risk of a disease (Richardson et al., 2004). It is 185 
straightforward to make these kind of statements in a Bayesian context, since they are 186 
directly obtained from the corresponding posterior distribution.  187 
 188 
Data  189 
Often health data are only available with location data supplied as a small area (known as 190 
areal data), rather than a street address geocoded to a latitude/longitude point. Determining 191 
the most appropriate region size to use involves several considerations (Box 3). This article 192 
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focuses on the application of disease mapping methods for areal data aggregated over small 193 
areas and omits the discussion of other forms of spatial data such as geostatistical and point 194 
patterns data. As an alternative, health outcome data may also be analysed at the individual 195 
level, while incorporating spatial information at any geographical scale such as a point or an 196 
area.  197 
 The data described in the Atlas (Cramb et al., 2011a) focused on Queensland cancer 198 
data aggregated to the SLA level, which was the smallest area with annual population data 199 
available. However, consistent with most administrative regions, the areas are of varying 200 
sizes, and larger areas tend to dominate the map. An alternative approach is to aggregate 201 
disease data with continuous coordinate information to regular grid cells; see Li et al. (2012a, 202 
2012b) and Kang et al. (2014). Such an approach allows modelling of disease data at a fine 203 
spatial scale, independent of administrative boundaries while preserving patient 204 
confidentiality. Using this approach, the spatial scale can be manipulated to a practically, 205 
geographically and computationally sensible scale. It does, however, require individual level 206 
geocoded data, which may not be accessible due to confidentiality concerns. Spatial data may 207 
also be available at various geographical scales and hence there is a need to combine 208 
information from multiple sources (see Gotway and Young (2002) for further details). 209 
Cramb et al. (2011a) mapped two health outcome measures in the Atlas, namely the 210 
incidence estimates and the relative survival estimates (discussed in the following Section). 211 
Incidence is a measure of the risk of developing a disease within a specified period of time. 212 
Relative survival is the standard measure of survival from a disease in population-based 213 
disease survival studies (Yu, 2013). Each of these outcomes require specific input data (refer 214 
to Boxes 4 and 5).  215 
Although other estimates of disease, such as prevalence, are beyond the scope of this 216 
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article,  Bayesian mapping approaches are described in Congdon (2006). 217 
 218 
Bayesian Spatial Statistical Models  219 
A response variable is the event studied and expected to vary whenever the independent 220 
variable is altered. It is also known as a dependent variable. Here we consider two response 221 
variables, namely the number of cancers diagnosed (incidence model) and the number of 222 
deaths within x years of diagnosis (relative survival model). Because both response 223 
distributions are counts, and the disease is less common, a Poisson distribution is used to 224 
model them (Box 6).  225 
 The resulting estimate for the incidence of a disease is known as the standardised 226 
incidence ratio or SIR (see Glossary), which is an estimate of relative risk within each area 227 
based on the population size, that compares the observed incidence against the expected 228 
incidence. The SIR explains if the observed incidence in a particular area is higher or lower 229 
than the average across all areas included, given the age and sex distribution and population 230 
size of the area.  231 
The relative survival of a disease is modelled using an excess mortality (see Glossary) 232 
model that contrasts the mortality in the background population with disease mortality. The 233 
survival model results in an excess hazard, which is called the relative excess risk (RER) (see 234 
Glossary). The RER informs the relative survival (see Glossary) of a disease within each 235 
area, by reporting the risk of death within a certain number of years of diagnosis after 236 
adjusting for broad age groups, compared to the average. The SIR and RER are further 237 
explained in Appendix A.  238 
Small-area disease data typically exhibit spatial correlation due to spatial structure in 239 
the unknown risk factors. The presence of spatial correlation can be caused by a combination 240 
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of socio-demographic clustering and environmental effects (Browning et al., 2003). 241 
Traditional regression models assume independence of random effects and so ignore the 242 
potential presence of spatial correlation. This may lead to false conclusions regarding 243 
covariate effects and unstable risk estimates (Fahrmeir and Kneib, 2011).  244 
 The spatial correlation can be accounted for using spatial smoothing techniques, by 245 
estimating the effect of interest at a location using the effect values at nearby locations 246 
(Wang, 2006). Spatial smoothing approaches based on neighbourhood dependence are widely 247 
employed in disease mapping where areas with a common boundary are treated as neighbours 248 
(Paciorek, 2013). By accounting for the spatial correlation, model inference, prediction and 249 
estimation can be improved (Haran, 2011). The effect of the arbitrary geographical 250 
boundaries can also be reduced via spatial smoothing. Other smoothing techniques include 251 
interpolation methods, kernel regression, kriging and partition methods (Lawson et al., 2003; 252 
Goovaerts, 2006a).  253 
 Two popular ways of defining a neighbourhood structure for the modelling of spatial 254 
correlation are the Queen definition and the Rook definition. The Rook method defines that 255 
two areas are considered neighbours if they share a common boundary whereas the Queen 256 
method specifies that two areas are termed neighbours if they share a common boundary or 257 
vertex. Following Earnest et al. (2007), the illustration of these two methods for defining a 258 
neighbourhood structure is given in Figure 1. Such information can be used to calculate the 259 
average of spatially correlated random effects of neighbours for area i.  260 
  The following Bayesian spatial models take the spatial correlation into account by 261 
incorporating spatially correlated random effects. Both the incidence and relative survival 262 
models assume a Poisson distribution for the observed data and contain spatial and 263 
unstructured (non-spatial) random effects. The well-known Bayesian spatial model of Besag 264 
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et al. (1991) is widely used to model disease incidence (Box 7) as it has desirable properties 265 
for disease mapping, particularly in modelling the geographical dependence between 266 
neighbouring areas (Best et al., 2005). The incidence model can also be used to model 267 
mortality.  268 
 With regard to relative survival, the excess mortality can be modelled via a 269 
generalized linear model, using exact survival times (Dickman et al., 2004). The excess 270 
mortality is the mortality that is attributable to a particular disease. It is a measure of the 271 
deaths which occur over and above those that would be expected for a given population. Such 272 
a Bayesian relative survival model (Box 8) has been used by Fairley et al. (2008) and Cramb 273 
et al. (2011a). See Appendix A for the statistical models for incidence and relative survival.  274 
 In both models, the spatial random effect is the component that accounts for spatial 275 
correlation between neighbouring areas. The unstructured or non-spatial random effect 276 
accounts for the unexplained variation in the model.  277 
In a Bayesian analysis, it is assumed that all parameters arise from a probability 278 
distribution. As such, distributions representing the likely spread of values are placed on each 279 
parameter. Commonly, a vague Normal distribution such as one with mean 0 and variance 280 
1.0×106 or Normal(0,1.0×106) is used for the intercept or coefficients of predictor terms (see 281 
Glossary). Vague priors refer to distributions with high spread, such as a Normal distribution 282 
with extremely large variance. Such a distribution gives similar prior value over a large range 283 
of parameter values.  284 
 Generally, the unstructured (non-spatial) random effects and the spatial random 285 
effects are both assigned a prior distribution with additional hyperparameters (Box 9). To 286 
allow for spatial correlation, commonly an intrinsic conditional autoregressive (CAR) 287 
distribution is used. The CAR prior models the spatial dependence in a study region by 288 
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effectively borrowing information from neighbouring areas than from distant areas and 289 
smoothing local rates toward local, neighbouring values. The method provides some 290 
shrinkage and spatial smoothing of the raw relative risk estimates (Clayton and Kaldor, 291 
1987). This results in a more stable estimate of the pattern of the underlying disease risk than 292 
that provided by the raw estimates. Consequently, the variance in the associated estimates is 293 
reduced and the spatial effect of geographical differences can be identified. This prior has 294 
been widely employed in disease mapping to study the geographical variation of disease risk 295 
(Clayton and Bernardinelli, 1992; Mollié, 1996; Wakefield et al., 2000), and works 296 
particularly well to smooth out variability not relevant to the underlying risk (Assunção and 297 
Krainski, 2009).  298 
 Commonly, both the precision (inverse of the variance) hyperparameters (see 299 
Glossary) are assigned a Gamma distribution. Alternative hyperprior distributions may 300 
include placing either a Uniform or half-Normal distribution on the standard deviation 301 
(square root of the variance) (Gelman and Hill, 2006).  302 
 The prior distributions used for the parameters may influence the results and therefore 303 
should be carefully considered and compared. There are two issues to consider when 304 
deciding on a prior distribution (Gelman, 2002): (a) what information is going into the prior 305 
distribution; and (b) the impact on the resulting posterior distribution. A sensitivity analysis 306 
(see Glossary) (Junaidi et al., 2011) can be used to investigate the dependence of the 307 
posterior distribution on prior distributions by comparing posterior inferences under different 308 
reasonable choices of prior distribution. A literature review is usually helpful to determine 309 
the prior distributions being used in similar Bayesian models.  310 
 311 
Computation  312 
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The complexity of these models mean they cannot be solved analytically. Instead, some 313 
method of approximation is required. One approach is to use Markov chain Monte Carlo 314 
(MCMC) methods (see Glossary), which samples from the posterior distribution. A variety of 315 
software is available to conduct MCMC, including BUGS (Bayesian inference Using Gibbs 316 
Sampling), JAGS (Just Another Gibbs Sampler), Stan and BACC (Bayesian Analysis, 317 
Computation & Communication). WinBUGS is one of the most popular options (Brooks et 318 
al., 2011) that provides great flexibility in Bayesian modelling, has a simple programming 319 
language (Crainiceanu et al., 2005) and interfaces with multiple statistical software, including 320 
R, Matlab, Stata and SAS. See Appendix B for the WinBUGS code for the discussed models. 321 
Some useful resources to help learn WinBUGS include Lawson et al. (2003), Lunn et al. 322 
(2012), Ntzoufras (2009), Lykou and Ntzoufras (2011), and Spiegelhalter (2003).  323 
 Bayesian computation for the above models can also be conducted in R (The R Core 324 
Team, 2012), by calling the inla program and adopting the integrated nested Laplace 325 
approximation (INLA) approach proposed by Rue et al. (2009). The INLA approach 326 
performs Bayesian inference for spatial models and is able to return accurate parameter 327 
estimates in a much shorter time than MCMC. The use of R-INLA for statistical analysis in 328 
various disciplines is increasingly common in recent years, including disease mapping. 329 
Appendix C provides R-INLA code to perform computation for the discussed models. Some 330 
useful resources for getting started with R-INLA include Schro¨dle and Held (2011a, 2011b), 331 
Blangiardo et al. (2013), and Rue et al. (2012). 332 
 To incorporate neighbourhood dependence into the Bayesian models, a 333 
neighbourhood matrix is required. The neighbourhood matrix contains a list of neighbours for 334 
an area. Freely available software programs that will calculate a neighbourhood matrix 335 
include GeoDa (Anselin et al., 2006), the spdep R package Bivand et al. (2011), or within 336 
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WinBUGS.  337 
 338 
Making Decisions  339 
Perhaps the greatest advantage of Bayesian methods is the diversity of options available to 340 
assist in the decision making process. Communicating results in a way that is easily 341 
interpretable and accurate enables informed decisions to be made. Here we outline some of 342 
the ways modelled estimates can be used and visualized.  343 
The SIR and RER estimates produced using the methods described in the previous 344 
sections are two commonly seen measures of disease risk. Appendices B and C outline the 345 
code required for producing the estimates. The estimates produced by Bayesian models give 346 
great flexibility in reporting results, including comparison of the risk estimates against the 347 
average, ranking estimates, and/or examining the uncertainty around the estimates.  348 
 Ranking of disease estimates ensures that public health investigations or interventions 349 
are prioritized correctly (Shen and Louis, 2000). In the Bayesian context, the posterior 350 
distributions of health outcome measures (such as SIR and RER) allow for the calculation of 351 
rank estimates of each area (Clayton and Kaldor, 1987; Lawson et al., 2000). For instance, 352 
Athens et al. (2013) use five health outcome measures to obtain county rank estimates for a 353 
composite health outcome measure. The five health outcome measures are converted to a 354 
score, and then ranked by weighted means. The ranking of health outcomes is useful for 355 
representing health performance of each area which can then be used to inform health 356 
decision making.  357 
 Moreover, comparison between two areas can be made easily in the Bayesian 358 
framework. Outside of Bayesian methods, it may be difficult and problematic to conduct a 359 
large number of pairwise comparisons for all areas using post-hoc tests (Jaccard et al., 1984). 360 
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The problem is that by conducting so many comparisons, the probability of finding some of 361 
the differences statistically significant by chance alone increases. The Bayesian context 362 
eliminates this issue with pairwise comparisons of the posterior distributions.  363 
 Bayesian methods produce measures of uncertainty for each modelled estimate. The 364 
uncertainty attached to the spatial distribution of risk values across the study region can be 365 
known as spatial uncertainty (Goovaerts, 2006b). It is valuable to visualize spatial uncertainty 366 
as it provides local details of the spatial variation of the risk, as well as an input to resource 367 
allocation, management and policy strategies. Several methods have been proposed to 368 
describe the uncertainty attached to the smoothed rates, including mapping the 95% credible 369 
interval (see Glossary) of the posterior distribution of smoothed rates (Johnson, 2004) and the 370 
probability that the risk in each small area exceeds a certain threshold (Richardson et al., 371 
2004).  372 
Under the Bayesian paradigm, there is great flexibility in communicating and 373 
visualising results. Options include maps or graphs of the smoothed estimates, their 374 
associated uncertainty, or the probabilities of being above/below certain values. Mapping of 375 
disease rates or outcomes facilitates comparison of spatial patterns in disease rates between 376 
males and females, between age groups, between races, over time, and motivates comparison 377 
with patterns of potential causes (Brewer and Pickle, 2002). By comparing disease rates of 378 
different areas, clues to possible causation may be found and this serves as a starting point for 379 
further investigation.  380 
 The purpose of this Section is to showcase various visualisations that can be produced 381 
using the outputs obtained from Bayesian modelling techniques and the associated 382 
interpretation. This is demonstrated on a common cancer with poor survival: male lung 383 
cancer in Queensland. Figures 2 to 7 present an array of maps or plots based on the results 384 
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from modelled survival (RER of death within 5 years of diagnosis) for each SLA that are 385 
useful for communicating the results of statistical analysis via the Bayesian paradigm. The 386 
RER expresses the risk of cancer patients dying from their cancer within five years of 387 
diagnosis in an SLA compared to the Queensland average (RER = 1), and therefore should 388 
not be directly compared between two SLAs. The figures were produced using the software 389 
R, package maptools.  390 
 Figure 2 maps the posterior distribution of SLA-level RER and provides a picture of 391 
the spatial pattern of the underlying risk. Figure 3 depicts the uncertainty associated with the 392 
Bayesian estimates of RER by mapping the 95th percentile (see Glossary) range of the 10000 393 
values sampled from the posterior distribution of RER for each SLA. A graph showing the 394 
ranked RER with the associated 95% credible interval for each SLA is provided in Figure 4. 395 
Horizontal box plots (see Glossary) of the RER estimates by socioeconomic status and 396 
rurality are provided in Figure 5 to provide additional information about where the extent of 397 
variability across the Queensland state. Figure 6 maps the SLAs having a 90% probability of 398 
RER being higher than the Queensland average (RER = 1) (highlighted in red) and the SLAs 399 
having at least a 90% probability of RER being lower than the Queensland average (RER = 400 
1) (highlighted in blue). Figure 7(a) depicts the probability of the SLAs having RER 401 
exceeding 1 and Figure 7(b) depicts the probability of the SLAs having RER exceeding 1.2. 402 
 403 
Discussion  404 
In this article we have outlined the benefits of Bayesian models for both analysis and 405 
visualization. The public health arena regularly makes practical decisions affecting people’s 406 
health. To facilitate decisions, it is vital that the analysis is conducted appropriately, and 407 
results are communicated effectively.  408 
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 Bayesian methods are increasingly being used to analyse routinely collected data. The 409 
Bayesian framework is now the tool of choice in many applied statistical areas, including 410 
disease mapping (Lawson et al., 1999). In small area studies, Bayesian methods often have 411 
better model fit than non-Bayesian smoothing methods (Lawson et al., 2000). Greater 412 
flexibility in distributional assumptions is possible under Bayesian methods than in 413 
traditional regression models (Waller and Gotway, 2004).  414 
 Whether to standardize response rates depends on the study objectives. For the cancer 415 
atlas, it was desirable to remove the influence of age, so that differences were not due to 416 
different age structures between areas. For incidence, we used the standardized incidence 417 
ratio (SIR), which adjusts for the area-specific age and sex structure. An alternative method 418 
to standardization for dealing with confounders is via the use of regression models 419 
(McNamee, 2005). These can be particularly useful when multiple confounders need to be 420 
controlled for simultaneously. For relative survival, we included age in the regression 421 
equation to remove its influence on the results. However, if the purpose of a study is to 422 
identify where the highest rates of disease are, such as for service provision, then there is no 423 
need to standardise (or otherwise adjust) the incidence rates. This is because the cause of the 424 
variation (whether sex, age or other factors), is inconsequential.  425 
 Visualising disease patterns through maps remains an effective method to convey a 426 
large amount of information in an engaging way. Few modern day visualisations include 427 
uncertainty measures, yet this greatly assists in decision making. Online, interactive 428 
visualisations can dynamically link maps (e.g. Figure 2 showing the smoothed Bayesian 429 
RER), with plots of the uncertainty (e.g. Figure 3 showing the 95% credible interval for each 430 
area). Selecting an area would then highlight the corresponding region in both plots, 431 
providing much greater information to the user.  432 
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 There are limitations associated with using routinely collected data. Determining the 433 
direction of causation may not be possible. Often there is a lag time between exposure and 434 
disease detection, and patients may move during this time. Bayesian methods also have 435 
certain limitations, including greater computational time if using Markov chain Monte Carlo 436 
approaches, and requiring sensitivity analyses to ensure priors are not exerting undue effect. 437 
With regard to computation using R-INLA, models must be expressible in the linear model 438 
format and there are restrictions on the types of prior distributions that can be assumed.  439 
However, we believe the advantages outlined in this article outweigh any limitations. 440 
Routinely collected data exist to enable disease monitoring and control. Appropriate analyses 441 
convert this data into information, which once communicated, enables action. Bayesian 442 
methods not only enable appropriate analyses to be performed, they also provide greater 443 
flexibility in visual communications.  444 
 Can descriptive studies really influence government policy? The disparities identified 445 
in the cancer atlas resulted in the Queensland government including a specific objective 446 
aimed at reducing the geographic disparities in cancer outcomes in their Strategic Directions 447 
(Statewide Health Service Strategy and Planning Unit, 2014). Results were also used in 448 
lobbying to increase the amount of financial assistance the government provided to remote 449 
patients to offset travel and accommodation costs while obtaining treatment away from home, 450 
and the amount provided was subsequently increased. Our experience is that routinely 451 
collected data, when appropriately analysed and communicated, facilitate appropriate 452 
government action.  453 
 We hope this article will enable greater understanding, and potentially uptake, of 454 
Bayesian methods in disease mapping, along with available options for communicating 455 
estimates and their uncertainty.  456 
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 457 
Appendix  458 
Appendix A Statistical models  459 
Appendix A.1 Incidence model  460 
Given a set of n areas, the statistical model for area i (i = 1, . . . , n) can be written as follows,  461 
 462 
 463 
where yi are the observed counts of area i, ei are the expected counts of area i, and θi is the 464 
SIR of area i. Here α is the intercept term, x is the predictor variable, and βk is the coefficient 465 
of the predictor variable. The component that accounts for spatial correlation between 466 
neighbouring areas is denoted by ui, and vi accounts for the unstructured (non-spatial) 467 
variation in the model.  468 
Appendix A.2 Relative survival model  469 
The statistical model can be written as  470 
 471 
 472 
where for age group k, follow-up interval j and area i; dijk is the number of deaths and μijk is 473 
the expected number of deaths. Here d∗ijk is the expected number of deaths due to causes 474 
other than the disease of interest and yijk is the person-time at risk. The intercept varied by 475 
follow-up year and is denoted by αj, x is the predictor variable, and βk is the coefficient of the 476 
predictor variable. Also, ui accounts for spatial dependence between neighbouring areas, and 477 
vi denotes the unstructured (non-spatial) random effects in the model.  478 
 
 
 
 
 
21 
 479 
Appendix B WinBUGS code  480 
Appendix B.1 WinBUGS code for the incidence model  481 
Model 482 
{ 483 
for (i in 1 : N) { 484 
# Likelihood 485 
O[i] ~ dpois(mu[i]) 486 
Opred[i] ~ dpois(mu[i]) 487 
log(mu[i]) <- log(E[i]) + alpha + u[i] + v[i] 488 
# Area-specific relative risk (for maps) 489 
RR[i] <- exp(alpha + u[i] + v[i]) 490 
# Prior distribution for the uncorrelated heterogeneity 491 
v[i] ~ dnorm(0, tauv) 492 
} 493 
# CAR prior distribution for spatial random effects 494 
u[1 : N] ~ car.normal(adj[], weights[], num[], tauu) 495 
for(k in 1:sumNumNeigh) { 496 
weights[k] <- 1 497 
} 498 
# Other priors: 499 
alpha ~ dflat() 500 
# Hyperpriors on precisions  501 
tauu ~ dgamma(0.1, 0.1) 502 
 
 
 
 
 
22 
tauv ~ dgamma(0.001, 0.001) 503 
sigmau <- sqrt(1 / tauu) 504 
sigmav <- sqrt(1 / tauv) 505 
#Standard deviations 506 
sdv <- sd(v[]) #marginal SD of heterogeneity 507 
sdu <- sd(u[]) #marginal SD of clustering 508 
} 509 
Appendix B.2 WinBUGS code for the relative survival model  510 
Model 511 
{ 512 
# Likelihood 513 
for (i in 1 : datarows) { 514 
d[i]  ~ dpois(mu[i]) 515 
mu[i]<-d_star[i] + excessd[i] 516 
log(excessd[i]) <-  log(y[i])+ alpha[RiskYear[i]] + 517 
beta[1]*agegp2[i] 518 
+ beta[2]*agegp3[i]+ u[slaNo[i]] + v[slaNo[i]] 519 
for (j in 1:N_RiskYear){ 520 
alpha[j] ~ dnorm (0, 0.001) 521 
} 522 
} 523 
# CAR prior for spatial effects 524 
u[1:Nsla] ~ car.normal(adj[], weights[], num[], tauu) 525 
for (k in 1:sumNumNeigh) {weights[k] <- 1 } 526 
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for (i in 1:Nsla) { 527 
# Prior distribution for the uncorrelated heterogeneity 528 
v[i] ~ dnorm(0, tauv) 529 
logRER[i]<-u[i]+v[i] 530 
RER[i]<-exp(logRER[i]) 531 
}  532 
# Other priors 533 
tauu ~ dgamma(0.5, 0.001) 534 
tauv ~ dgamma(0.5, 0.001) 535 
varv <- 1/tauv 536 
varu_con <-1/tauu 537 
varu_marg<-sd(u[])*sd(u[]) 538 
} 539 
 540 
Appendix C R-INLA code  541 
Appendix C.1 R-INLA code for the incidence model  542 
Assume that data are available for a set of areas as {yi,ei,x1i,x2i} for i = 1,...,n, where yi is a 543 
count, ei is an expected count, and x1i and x2i are two predictors/covariates. These data 544 
should be read into R as vectors and can be held in a list. In the code below, n represents the 545 
number of areas, obs represents disease count, expe represents expected count, cov1 and 546 
cov2 represent the covariates, u represents the spatial random effects, and v represents the 547 
unstructured (non-spatial) random effects.  548 
u=seq(1:n) 549 
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v=seq(1:n) 550 
data.incid = list(obs=obs, expe=expe, cov1=cov1, cov2=cov2, u=u, 551 
v=v) 552 
formula1 = obs ~ cov1 + cov2 553 
 + f(u, model="besag", graph="queensland.graph", param=c(0.1, 0.1)) 554 
 + f(v, model="iid", param=c(0.001, 0.001)) 555 
result1 = inla(formula1, family="poisson", data=data.incid, 556 
control.compute=list(dic=TRUE, cpo=TRUE, mlik=TRUE), E=expe) 557 
summary(result1) 558 
Appendix C.2 R-INLA code for the relative survival model  559 
In the code below, n represents the number of areas, d represents the number of deaths (dijk), 560 
d_star represents the expected number of deaths due to causes other than the disease of 561 
interest (d∗ijk), y represents the person-time at risk (yijk), cov1 and cov2 represent the 562 
covariates, u represents the spatial random effects, and v represents the unstructured (non-563 
spatial) random effects.  564 
u=seq(1:n) 565 
v=seq(1:n) 566 
data.surv = list(d=d, d_star=d_star, y=y, cov1=cov1, cov2=cov2, u=u, 567 
v=v) 568 
formula2 = d ~ offset(d_star) + cov1 + cov2 569 
 + f(u, model="besag", graph="queensland.graph", param=c(0.5, 570 
0.001)) 571 
 + f(v, model="iid", param=c(0.5, 0.001)) 572 
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result2 = inla(formula2, family="poisson", data=data.surv, 573 
   control.compute=list(dic=TRUE, cpo=TRUE, mlik=TRUE), E=y) 574 
summary(result2) 575 
 576 
Appendix D Glossary 577 
Box plot A visual display that summarizes data using a “box and whiskers” 
format to show the minimum and maximum values (ends of the 
whiskers), interquartile range (length of the box), and median (line 
through the box). 
Case-control study A type of observational analytic study. Enrollment into the study is 
based on presence (“case”) or absence (“control”) of disease. 
Characteristics such as previous exposure are then compared 
between cases and controls. 
Covariate  In statistics, a covariate is a variable that is possibly predictive of 
the outcome under study. A covariate may be of direct interest or it 
may be a confounding or interacting variable. 
Credible interval  An interval in the domain of a posterior probability distribution 
used for interval estimation. A 95% credible interval is interpreted 
as “a 95% probability the true estimate lies in this range” 
Direct method of 
standardisation  
Apply stratum-specific rates observed in the populations of interest 
to a standard population. The ratio of two directly standardised 
rates is called the comparative incidence ratio. 
Excess mortality  A measure of the deaths which occur over and above those that 
would be expected for a given population. These are deaths 
considered to result from the disease of interest  
Hierarchical model  A model written in a hierarchical form or in terms of sub-models  
Hierarchical structure  A hierarchy of parameters which are related to one another in a 
model 
Hyperparameter  A parameter in a hyperprior distribution  
Hyperprior 
distribution  
A prior distribution on a hyperparameter, i.e., on a parameter of a 
prior distribution 
Incidence  A measure of the risk of developing a disease within a specified 
period of time  
Indirect method of 
standardisation  
 
 
Apply stratum-specific reference rates to the populations of 
interest. The ratio of two indirectly standardised rates is called the 
SIR. 
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Inference, statistical  In statistics, the development of generalizations from sample data, 
usually with calculated degrees of uncertainty. 
Likelihood Likelihood is a tool for summarizing the data’s evidence about 
unknown parameters. It is the probability of a given sample being 
randomly drawn regarded as a function of the parameters of the 
population. 
Markov chain  A mechanism for generating plausible parameter value, whereby 
the value to be drawn depends on the previously drawn value in 
some way 
Markov chain Monte 
Carlo (MCMC)  
A class of algorithms for sampling from probability distributions by 
constructing a Markov chain that has the desired distribution as its 
equilibrium distribution  
Parameter A value used to represent a certain population characteristic which 
is usually unknown and therefore has to be estimated 
Percentile  The set of numbers from 0 to 100 that divide a distribution into 100 
parts of equal area, or divide a set of ranked data into 100 class 
intervals with each interval containing 1/100 of the observations. A 
particular percentile, say the 5th percentile, is a cut point with 5 
percent of the observations below it and the remaining 95% of the 
observations above it. 
Posterior distribution  A probability distribution on the values of an unknown parameter 
that combines prior information about the parameter contained in 
the observed data to give a composite picture of the final 
judgements about the values of the parameter  
Predictor A predictor variable is also known as an independent variable 
Prevalence The number or proportion of cases or events or conditions in a 
given population. 
Prior distribution  A probability distribution that represents the uncertainty about the 
parameter before the current data are examined 
Random effects  Effects that account for differences among the individual 
observational units in the sample, which are randomly sampled 
from the population. These effects usually conform to a specified 
distribution (typically a Normal distribution) and have a mean of 0  
Regression  A statistical technique for estimating the relationships among 
variables. 
Relative excess risk 
(RER)  
A measure that informs the relative survival of a disease, by 
reporting the risk of death within a certain number of years of 
diagnosis after adjusting for broad age groups, compared to the 
average 
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Relative risk A comparison of the risk of some health-related event such as 
disease or death in two groups. 
Relative survival  A standard measure of excess mortality due to a disease in 
population-based disease survival studies  
Risk factors An aspect of personal behavior or lifestyle, an environmental 
exposure, or an inborn or inherited characteristic that is associated 
with an increased occurrence of disease or other health-related 
event or condition. 
Sensitivity analysis  A sensitivity analysis is the study of how the uncertainty in the 
output of a mathematical model or system (numerical or otherwise) 
can be apportioned to different sources of uncertainty in its inputs. 
Standardised 
incidence ratio (SIR)  
An estimate of relative risk within each area based on the 
population size, that compares the observed incidence against the 
expected incidence  
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Box 1: Bayesian model  
Given Bayes’ theorem (Gelman et al. 2014), 
 
The posterior distribution ( ) is proportional to the prior distribution for 
parameters ( ) multiplied by the data-based distribution given parameters (also 
known as the likelihood (see Glossary)) ( ). 
• Posterior estimates (model output) are a combination of the prior information and 
the data  
• Parameters in the model are assigned prior distributions   
• A prior distribution is the probability distribution that represents the uncertainty 
about the parameter before the current data are examined   
• Parameters in the prior distribution can also be assigned distributions   
• Parameters in the prior distribution (called ‘hyperparameters’) can also be assigned 
distributions  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Box 2: Normal distribution  
A distribution contains information on every possible observation and its associated 
probability. For instance, a Normal distribution is a continuous distribution that is 
“bell-shaped”, at which data are most likely to be distributed around the mean and are 
less likely to be farther away from the mean. A Normal distribution is often specified 
in terms of its mean (μ) and variance (σ2) and can be written in the form of Normal(μ, 
σ2). A parameter can be assigned a Normal distribution with mean 0 and variance 100 
which can be denoted as parameter Normal(0, 100). Alternatively, instead of 
specifying the values (0, 100), uncertainty about these parameters can also be 
described probabilistically. For example, instead of specifying ‘100’ for the variance, 
the prior distribution could be written as Normal(0, σ0
2) and then σ0
2 is described by 
another probability distribution. Here σ0
2 is termed a hyperparameter (see Glossary) 
and the distribution on σ0
2 a hyperprior distribution (see Glossary).  
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Box 3: Selecting regional scale  
Important questions to consider when deciding on an appropriate area scale to conduct 
the analysis include:  
1. Is there a risk of patient confidentiality being compromised?  
2. Are population data available at the same scale as disease occurrences?  
3. Will boundaries change over time? If so, what options are possible for keeping your 
data consistent?   
4. Is there a digital boundary file available?   
5. Will areas have a practical and relevant interpretation?   
6. How does the size of the areas compare relative to the spatial pattern of the 
variation? If there is a lot of variation in an environmental effect within areas, this will 
limit the scope to measure the effect.   
7. How many areas will there be? This affects computational time.   
8. Are some areas likely to have zero population? This is likely to cause difficulties in 
modelling and estimation, e.g., zero denominator causes difficulties when using a 
Poisson distribution.   
9. What scale have other similar studies used?   
10. What spatial scale is available for covariate data? If spatial variation that takes 
fixed effects into account is of interest, it is not necessary to have a spatial scale finer 
than the available covariate data.  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Box 4: Data required to produce incidence estimates  
Given a disease of interest, the information required to produce incidence estimates 
includes  
• Number of disease cases among people within a certain time period for each small 
area  
• Estimated population counts by age group, sex, year and small area of residence − 
this is used as the denominator for calculating rates and for age-standardisation (see 
Glossary direct and indirect methods of standardisation)    
• Geographical boundaries − this is used to compute the adjacency matrix required 
for spatial smoothing   
• Optional: any desired small area level covariates (if available) such as rurality and 
socioeconomic status  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Box 5: Data required to produce survival estimates  
To produce relative survival estimates of a disease of interest, the input data required 
include  
• From the patients with the disease of interest (if not available for each individual 
then aggregated over each small area, any covariates and follow-up time intervals):  
− The observed number of deaths (from any cause) within a certain time period  
− Person-time at risk (the length of time between diagnosis and either death or 
censoring)   
• General population mortality data used to calculate the expected number of deaths, 
which represents deaths due to causes other than the disease of interest for each 
small area, sex and broad age group  
• Geographical boundaries − this is used to compute the adjacency matrix required for 
spatial smoothing  
• Optional: individual or area-level covariates, including age, tumour stage, or area 
rurality and socioeconomic status  
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Box 6: Probability distributions used in epidemiology  
• For common diseases, the Binomial distribution models the number of disease 
occurrences in a sample size n from a population size N. The Binomial distribution 
is also commonly used in the analysis of disease prevalence data and case-control 
studies (see Glossary) (Thomas, 2014).  
• When the disease is rare or less common (i.e., the probability of a disease is small), 
the Poisson distribution is used as an approximation to a Binomial distribution 
(Wakefield, 2003, 2004). A Poisson distribution expresses the probability of a 
given number of events occurring in a fixed interval of time and/or space. 
• For over-dispersed count distributions (where the data admit more variability than 
expected under the assumed distribution), a Negative Binomial distribution may be 
appropriate (Gardner et al., 1995). 
• For empirical data that show more zeroes than would be expected, zero-inflated 
models may be employed (Gardner et al., 1995). 
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Box 7: The incidence model  
Given a set of n areas, the model for area i (i = 1,, n) can be written as follows,  
Observed counts in area i ∼ Poisson(expected counts of area i × SIR of area i),  
log(SIR of area i) = intercept term + coefficient × predictor variable vector for area i 
+ spatial random effect of area i + unstructured random effect of area i.  
o Apply stratum-specific reference rates to the populations of interest.  
o The ratio of two indirectly standardised rates is called the SIR. 
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Box 8: The relative survival model  
The model can be written as below, where for area i, follow-up interval j, and age 
group k,  
Number of deaths(ijk) ∼ Poisson(expected number of deaths(ijk)),  
log(expected number of deaths(ijk) − expected number of deaths due to causes other 
than disease of interest(ijk)) = log(person-time at risk(ijk)) + intercept varied by 
follow-up year j + coefficient(k) × predictor variable vector + spatial random effect of 
area i + unstructured random effect of area i.  
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Box 9: Prior distributions for the random effects  
Unstructured 
The unstructured random effects are assumed to follow a Normal distribution with mean zero 
and a hyperparameter for variance.  
Unstructured random effect of area i ∼ Normal(0, variance hyperparameter).  
 
Spatial 
The spatial random effects are assumed to follow a conditional autoregressive (CAR) prior 
(Besag et al., 1991) with some hyperparameters, as follows  
Spatial random effect of area i ∼ Normal (average of spatial effects of neighbours of area i, 
variance hyperparameter / number of neighbours of area i).
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Figure 1: The representation of neighbourhood structure of area i. Based on the Rook 907 
method, neighbours for area i include areas 2, 4, 6 and 8, while the Queen method defines 908 
regions 1 − 8 as neighbours of area i. 909 
 910 
 911 
 912 
 913 
 914 
 915 
 916 
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Figure 2: Bayesian smoothed estimate of RER. To show the spatial pattern of the 918 
underlying risk, the median of the posterior distribution of SLA-level RER is mapped. An 919 
inset of South-East Queensland is provided for greater detail as this region has a large 920 
number of SLAs. Thematic categories are based on fixed breaks method.  921 
 922 
 923 
 924 
 925 
 926 
 927 
 928 
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Figure 3: Uncertainty of Bayesian smoothed estimate of RER. This map depicts the 930 
uncertainty associated with the estimates of relative risk. The 95th percentile range (97.5th 931 
minus the 2.5th percentile) of the 10000 values sampled from the posterior distribution of 932 
RER for each SLA is mapped here. An inset of South-East Queensland is provided for 933 
greater detail as this region has a large number of SLAs. Thematic categories are based on 934 
quintiles.  935 
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Figure 4: Uncertainty of Bayesian smoothed estimate of RER. The 95% credible interval 940 
(97.5th − 2.5th percentile) of the 10000 values sampled from the posterior distribution of 941 
RER for each SLA is plotted here. This plot shows how much reliance can be placed on the 942 
estimates. The black line is the median RER for each SLA. The blue vertical lines are the 943 
95% credible intervals, and indicate the amount of uncertainty associated with each estimate. 944 
The red line shows the Queensland average (set to 1).  945 
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(a) Socioeconomic status 957 
 958 
(b) Rurality 959 
Figure 5: Distribution of smoothed RER estimates according to (a) Socioeconomic status 960 
(b) Rurality. The distributional plots reflect the general patterns in the smoothed RER 961 
estimates across the area-based categories of socioeconomic status and rurality. These plots 962 
show the proportion of RER estimates that are above or below the Queensland average 963 
(vertical red line) within each of the area-based categories. The plots only present the range 964 
of point estimates, and so do not take the amount of uncertainty associated with each SLA-965 
specific estimate into account.  966 
 
 
 
 
 
47 
 967 
Figure 6: In the Bayesian paradigm, the SLAs highlighted in red have a 90% probability of 968 
RER being higher than the Queensland average (RER = 1). This means that the lower 10th 969 
percentile of the posterior distribution of RER exceeds 1. The SLAs highlighted in blue 970 
express at least a 90% probability of RER being lower than the Queensland average (RER = 971 
1). This means that the upper 90th percentile of the posterior distribution of RER is less than 972 
1. The density plots show the posterior distribution of RER for four randomly chosen SLAs 973 
where the x-axis is the RER values. The two density plots on the left show that there is more 974 
than 90% chance for the RER to be higher than 1. The two density plots on the right show 975 
that there is more than 90% chance for the RER to be lower than 1. The percentage of low 976 
risk or high risk for each SLA is also given in each density plot. An inset of South-East 977 
Queensland is provided for greater detail as this region has a large number of SLAs.  978 
 979 
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(a) 981 
 982 
(b) 983 
Figure 7: (a) Thematic map depicting the probability of RER exceeding 1. (b) Thematic 984 
map depicting the probability of RER exceeding 1.2. The threshold 1.2 was chosen to 985 
reflect high risk as it lies in the fifth quintile. Four SLAs are chosen to demonstrate how the 986 
probabilities change when the thresholds change. An inset of South-East Queensland is 987 
provided for greater detail as this region has a large number of SLAs. 988 
